Human CNS Tau Kinetics in Tauopathies
| Status: | Recruiting |
|---|---|
| Conditions: | Neurology, Neurology, Neurology, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/26/2018 |
| Start Date: | August 21, 2017 |
| End Date: | December 31, 2019 |
| Contact: | Melissa M Sullivan |
| Email: | m.sullivan@wustl.edu |
| Phone: | 314-747-4857 |
The goal of this study is to characterize tau kinetics and tau aggregation in the human CNS
and to test the hypothesis that tau kinetics are altered (i.e. increased production,
decreased clearance, and increased aggregation rate) in tauopathies.
and to test the hypothesis that tau kinetics are altered (i.e. increased production,
decreased clearance, and increased aggregation rate) in tauopathies.
Tauopathies are neurodegenerative diseases with tau pathology. These tauopathies are the most
common pathology in neurodegenerative diseases, and they are reaching epidemic proportions.
The rates of tau kinetics are central to understanding normal and abnormal processing and
production and clearance of tau kinetics in humans to help understand the causes of tauopathy
and evaluate tau-targeted therapeutics.
This study will utilize the Stable Isotope Labeling Kinetics (SILK) method to elucidate tau
kinetics in vivo in the human central nervous system (CNS) and its alteration in tauopathies.
A total of ~34 participants from 3 different neurodegenerative diseases: Frontotemporal
Dementia (FTD), Corticobasal Degeneration (CBD), and Progressive Supranuclear Palsy (PSP),
will be invited to enroll in the study.
Participants will be labeled with stable isotopes via 16hr intravenous infusion and CSF
samples collected during subsequent lumbar puncture visits over ~120 days. CSF will be
analyzed over time for the quantitation of labeled tau.
common pathology in neurodegenerative diseases, and they are reaching epidemic proportions.
The rates of tau kinetics are central to understanding normal and abnormal processing and
production and clearance of tau kinetics in humans to help understand the causes of tauopathy
and evaluate tau-targeted therapeutics.
This study will utilize the Stable Isotope Labeling Kinetics (SILK) method to elucidate tau
kinetics in vivo in the human central nervous system (CNS) and its alteration in tauopathies.
A total of ~34 participants from 3 different neurodegenerative diseases: Frontotemporal
Dementia (FTD), Corticobasal Degeneration (CBD), and Progressive Supranuclear Palsy (PSP),
will be invited to enroll in the study.
Participants will be labeled with stable isotopes via 16hr intravenous infusion and CSF
samples collected during subsequent lumbar puncture visits over ~120 days. CSF will be
analyzed over time for the quantitation of labeled tau.
Inclusion Criteria:
- Diagnosed with PSP, CBD, or FTD MAPT
Exclusion Criteria:
- Clotting disorder
- Active anticoagulation therapy
- Active infection
- Meningitis
- Recent syncope
- Current experimental treatment targeting Aβ or medications thought to influence Aβ
production or clearance rates (benzodiazepines, muscarinic agents, or anti-epileptics)
We found this trial at
1
site
Saint Louis, Missouri 63110
Principal Investigator: Randall J Bateman, MD
Phone: 314-747-4857
Click here to add this to my saved trials
